Treatment of primary membranous nephropathy: where are we now?

Andrea Angioi, Nicola Lepori, Ana Coloma López, Sanjeev M Sethi, Fernando Custodio Fervenza, Antonello Pani

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalJournal of Nephrology
DOIs
StateAccepted/In press - Sep 5 2017

Keywords

  • Glomerulopathies
  • Immunosuppression
  • Membranous glomerulonephritis
  • Renal diseases

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Treatment of primary membranous nephropathy: where are we now?'. Together they form a unique fingerprint.

Cite this